Sigyn Therapeutics, Inc. Announces Participation in the Q3 Virtual Investor Summit

San Diego, California--(Newsfile Corp. - August 17, 2021) - Sigyn Therapeutics, Inc. (OTC Pink: SIGY) today announced that Jim Joyce, Chairman & CEO will be attending the Q3 Virtual Investor Summit.

About Sigyn Therapeutics, Inc.

Sigyn Therapeutics™ is focused on a significant unmet need in global health; the treatment of life-threatening inflammatory conditions that are precipitated by Cytokine Storm Syndrome. To calm the Cytokine Storm, Sigyn Therapy™ extracts pathogen sources of inflammation, deadly toxins and relevant inflammatory mediators from the bloodstream. In vitro blood purification studies have validated the ability of Sigyn Therapy to address viral pathogens (including COVID-19), bacterial endotoxin, relevant inflammatory cytokines (Interleukin-6, Interleukin-1b, tumor necrosis factor-alpha) and hepatic toxins (ammonia, bilirubin, bile acid). An additional study modeled the ability of Sigyn Therapy ability to address CytoVesicles that transport inflammatory cargos throughout the bloodstream. The Company also conducted a first-in-mammal pilot study that demonstrated the safe administration of Sigyn Therapy during six-hour treatment exposures. Sigyn Therapy is a single-use blood purification technology designed for use on the established infrastructure of hemodialysis and continuous renal replacement therapy (CRRT) machines located in hospitals and clinics worldwide. In contrast to blood purification therapies that concentrate inflammatory targets in the blood-path, Sigyn Therapy extracts targets out of the bloodstream to eliminate any continued interactions with blood cells. Incorporated within Sigyn Therapy is a formulation of adsorbent components that provide more than 170,000 square meters of surface areas on which to adsorb and remove bloodstream targets. This equates to more than 40 acres of surface adsorption area in each Sigyn Therapy device. The Company plans to submit an Investigational Device Exemption (IDE) to The United States Food and Drug Administration (FDA) to support the potential initiation of human clinical studies in 2022.Cytokine Storm Syndrome is often induced by an infectious pathogen. The hallmark indicator of the Cytokine Storm is an uncontrolled release of pro-inflammatory cytokines, which can destroy tissue, cause multiple organ failure and lead to death. The annual market opportunity to address Cytokine Storm related indications exceeds $20 billion and includes sepsis, the most common cause of hospital deaths. Virus-induced Cytokine Storm Syndrome is a leading cause of death resulting from severe SARS-CoV-2 (COVID-19) infections.To learn more, visit www.SigynTherapeutics.com^[1].

For further information:

Sigyn Therapeutics, Inc.Jim Joyce619.368.2000jj@sigyntherapeutics.com^[2]

About the Investor Summit

The Investor Summit^[3] is an exclusive, independent conference dedicated to connecting smallcap and microcap companies with qualified investors. The Q3 Investor Summit will take place virtually, featuring 80+ companies and over 800 investors, consisting of institutional investors, family offices, and private wealth.

To request complimentary investor registration: please click here: Complimentary Investor Registration^[4]

Contact:

Sasha Murray at sasha@investorsummitgroup.com^[5]